Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) decreased during the last reporting period, falling from 174.14M to 173.93M. This put 35.4% of the company's publicly available shares ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果